Article Per Year (5 Year)
p-Index From 2021 - 2026
4.333
P-Index
This Author published in this journals
All Journal Indonesian Journal of Tropical and Infectious Disease Jurnal Pengabdian Kepada Masyarakat (Indonesian Journal of Community Engagement) Majalah Kesehatan FKUB Jurnal Respirologi Indonesia Jurnal Respirasi (JR) Jurnal Ilmiah Akuntansi dan Bisnis JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) Jurnal Abdi Insani JOURNAL OF COMMUNITY MEDICINE AND PUBLIC HEALTH RESEARCH Indian Journal of Forensic Medicine & Toxicology Narra J Jurnal Perak Malahayati : Pengabdian Kepada Masyarakat JUMANTIK (Jurnal Ilmiah Penelitian Kesehatan) Indonesian Journal of Cancer Jurnal Keperawatan Ophthalmologica Indonesiana Folia Medica Indonesiana
Laksmi Wulandari
Departement Of Pulmonology, Faculty Of Medicine, Airlangga University
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Civil Engineering, Building, Construction & Architecture Computer Science & IT Decision Sciences, Operations Research & Management Earth & Planetary Sciences Economics, Econometrics & Finance Education Engineering Environmental Science Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Mathematics Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 41 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 41 Documents
Search

 1   2   3   4   5 
PEMANFAATAN MEDIA DARING AUDIOVISUAL SEBAGAI SARANA EDUKASI PERAN GENETIKA MANUSIA PADA PENYAKIT INFEKSI Hamidah, Berliana; Pakpahan, Cennikon; Puteri, Rr. Astrid Aulia Artiono; Farahannisaa, Kintan Adelia; Wulandari, Laksmi; Wibawa, Tri; Prakoeswa, Cita Rosita Sigit
Jurnal Abdi Insani Vol 12 No 3 (2025): Jurnal Abdi Insani
Publisher : Universitas Mataram

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29303/abdiinsani.v12i3.2386

Abstract

Penyakit infeksi merupakan penyakit dengan insidensi tinggi di Indonesia sebagai negara tropis. Dewasa ini, berbagai penelitian tidak hanya seputar agen penyebab (bakteri, virus, parasit) ataupun faktor lingkungan saja, namun juga banyak melibatkan inang, termasuk genetika manusia. Pengabdian masyarakat ini bertujuan mengedukasi sasaran terbatas yaitu akademisi, mahasiswa, peneliti, dan klinisi di bidang kedokteran dan kesehatan di Indonesia tentang peran genetika manusia dalam penyakit infeksi. Pengabdian masyarakat dilakukan dengan membuat media daring audiovisual berupa tanya jawab bersama pakar dengan evaluasi setelah satu bulan dari pengunggahan video. Hasil pengabdian masyarakat menunjukkan bahwa penggunaan media daring audiovisual efektif dalam meningkatkan pemahaman akademisi, mahasiswa, peneliti, dan klinisi mengenai peran genetika manusia dalam penyakit infeksi. Diskusi dengan responden menghasilkan daftar pertanyaan yang relevan, yang kemudian dijawab oleh pakar melalui video edukatif. Video ini diunggah dan dibagikan kepada sasaran terbatas, memperoleh 48 penayangan serta respon positif dalam satu bulan. Evaluasi menunjukkan perlunya distribusi lebih luas untuk meningkatkan dampak edukasi. Model serupa dapat dikembangkan untuk memperluas jangkauan edukasi kedokteran berbasis daring. Pemanfaatan media daring audiovisual dalam pengabdian masyarakat bagi akademisi, mahasiswa, peneliti, dan klinisi di bidang kedokteran dan kesehatan meningkatkan pemahaman tentang peran genetika manusia pada penyakit infeksi. Untuk memperluas dampaknya, distribusi konten perlu diperluas. Model edukasi serupa dapat dikembangkan lebih lanjut untuk menjangkau masyarakat luas, seiring dengan kemajuan teknologi dan kebutuhan informasi kesehatan yang terus berkembang.
The Time to Progression in Lung Adenocarcinoma Patients Receiving First- and Second-Generation EGFR-TKI in Indonesia Syahruddin, Elisna; Soeroso, Noni Novisari; Ananda, Fannie Rizki; Wulandari, Laksmi; Setijadi, Ana Rima; Ermayanti, Sabrina; Pratiwi, Suryanti Dwi; Infianto, Andreas; Andayani, Novita; Munir, Sri Melati; Pratama, Avissena Dutha; Kusumawardani, Ida Ayu Jasminarti Dwi; Haryati, Haryati; Duyen, Natalie; Hanif, Muhammad Alfin; Lim, Darren Wan-Teck
Jurnal Respirasi Vol. 11 No. 1 (2025): January 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.1.2025.22-30

Abstract

Introduction: Targeted therapy, particularly epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for non-small cell lung cancer (NSCLC). However, drug resistance has grown in the last few decades. This study compared the progression time of lung cancer patients treated with first- and second-generation EGFR-TKI. Methods: Based on cytology and histological results, this cross-sectional study included 1,008 participants diagnosed with lung adenocarcinoma (LUAD) from 11 Indonesian Respiratory Centers. Every three months, the response to treatment was assessed using the Response Evaluation Criteria in Solid Tumours (RECIST) criteria in 1.1. Significant differences in the clinical features of the three TKI treatment groups were identified using logistic regression analysis, the median time to disease progression was estimated using the Kaplan-Meier technique, and independent prognostic factors related to the time to progression (TTP) were assessed using Cox proportional hazards regression. Results: This study examined 505 patients, the majority of whom were females (50.9%), never smoked (59.8%), diagnosed at an advanced stage (99.2%), and had an Eastern Cooperative Oncology Group (ECOG) scale of 0-1 (83.2%). Approximately 98.1% of patients were treated with afatinib (14.8%), erlotinib (18.6%), and gefitinib (66.1%) due to common mutations. The groups did not differ significantly (p>0.05). The median overall survival (OS) rate was 9 months. The time to LUAD progression in lung cancer was significantly impacted by poor performance (p=0.001). Conclusion: Epidermal growth factor receptor-tyrosine kinase inhibitor treatment can only prolong the TTP of LUAD by up to 9 months, and the performance scale when receiving the EGFR-TKI significantly affects the prognosis.
Primary Pulmonary Myxoid Sarcoma: A Rare and Challenging Diagnosis in Thoracic Oncology Apriyanto, Yudi; Febriani, Anna; Wulandari, Laksmi; Wati, Farah Fatma
Jurnal Respirasi Vol. 11 No. 1 (2025): January 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.1.2025.69-74

Abstract

Introduction: Primary pulmonary myxoid sarcoma (PPMS) is a rare malignant mesenchymal lung tumor, with fewer than 40 cases reported worldwide. This care report presented a case of PPMS with surgical difficulties. Case: A 53-year-old man presented with a six-month history of exertional dyspnea, coughing up blood, right chest pain, anorexia, and weight loss. Thoracic computed tomography (CT) imaging revealed an enhancing solid mass in the middle-posterior mediastinum. Histopathological examination of a core biopsy identified anaplastic lipoblast cells indicative of liposarcoma. Based on the multidisciplinary team (MDT) discussion, the patient was diagnosed with mediastinal liposarcoma, and tumor excision was planned. However, during the surgery, a lung tumor with adhesions to the middle and lower lobes of the right lung was discovered, precluding the complete tumor. An open biopsy was performed instead, revealing a proliferation of anaplastic cells with round to oval spindle nuclei arranged reticularly within a myxoid stroma, along with positive Alcian blue staining. Immunohistochemical analysis demonstrated focal desmin positivity in the cytoplasm of the tumor cells. The diagnosis of PPMS was confirmed based on the criteria by the World Health Organization (WHO) in 2021, including primary lung tumor, spindle-shaped and round tumor cells in a reticular pattern within a myxoid stroma, and immunohistochemical findings that exclude other histologically similar tumors. Conclusion: Although rare, PPMS should be considered in the differential diagnosis of thoracic tumors. Most PPMS patients were treated surgically and had a good prognosis. However, tumor excision could not be performed in this patient due to the adhesion of the tumor mass to the middle and lower lobes of the right lung.
Indonesian Society of Respirology Position Paper on Lung Cancer Control in Indonesia Andarini, Sita; Santoso, Andintia Aisyah; Arfiansyah, Mochammad Aris; Syahruddin, Elisna; Zaini, Jamal; Putra, Andika Chandra; Kurniawan, Ferry Dwi; Ermayanti, Sabrina; Soeroso, Noni Novisari; Munir, Sri Melati; Infianto, Andreas; Setijadi, Ana Rima; Setyawan, Ungky Agus; Wulandari, Laksmi; Haryati, Haryati; Jasminarti, Ida Ayu; Hidayat, Moulid; Santoso, Arif
Jurnal Respirologi Indonesia Vol 44 No 4 (2024)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v44i4.884

Abstract

Lung cancer is a major health concern in Indonesia due to its increasing prevalence, late-stage diagnosis, younger population, and high mortality. Addressing this issue requires nationwide implementation of comprehensive lung cancer control, which includes risk reduction and prevention strategies, focusing on tobacco control and air pollution mitigation. Screening with low-dose computed tomography (LDCT) and early detection in symptomatic patients, along with TB screening programs and all non-communicable diseases, is strongly recommended to enhance early case findings, treatment effectiveness, and overall patient outcomes. A multidisciplinary team (MDT) approach is important to ensure accurate diagnosis and comprehensive care. Moreover, the integration of palliative care at the early stages of advanced lung cancer is vital, focusing on symptom management and enhancing the quality of life for patients. While national guidelines are available for the diagnosis and treatment of lung cancer, significant disparities in healthcare access remain across Indonesia. Thus, it is essential to improve universal health coverage and referral systems to guarantee equal access to lung cancer care for patients at all levels through advocacy and ease of access.
Mediastinal Non-Hodgkin's Lymphoma Metastatic to Right Atrium Mimicking Right Atrial Myxoma Khusnurrokhman, Gemilang; Wulandari, Laksmi
Folia Medica Indonesiana Vol. 57, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Highlight: • A 32-year-old male patient suffered mediastinal non-hodgkin's lymphoma metastatic to the right atrium which mimicked right atrial myxoma. • The patient died of suspected mediastinal NHL thromboembolism that spread in the right atrium. Abstract: In this case report, the anatomical pathology results in the form of B cell type LNH, but at the age of 32 years and the risk factor in this patient was a former active smoker. In the anatomical pathology results, the results of the B-High Grade Cell Type LNH were also obtained. B-cell type non-hodgkin's lymphoma can be mutated in the MYC gene (v-myc avian myceloctomatosis viral oncogene homolog) and the BCL-2 and BCL-6 (B-cell lymphoma) genes. If this morphology is found, then the patient's prognosis is poor. Most of these patients were males and the incidence was in the mediastinal area. Mediastinal NHL could develop and enlarge to involve the heart and pericardium. The spread could occur directly and lymphogens. These metastatic tumors were often misdiagnosed with atrial myxoma. In this case report, exploration of the right atrium and open mediastinal biopsy was performed. An open biopsy of the mediastinum revealed a mediastinal mass that enlarged to enter the right atrium. Atrial myxoma was not found. Primary lymphoma growth could also occur in the heart. This condition was called primary cardiac lymphoid (PCL). This case was very rare and was often considered an atrial myxoma. The patient died 10 days after discharge from the hospital. While the patient was eating, the patient had a seizure and the patient was immediately taken to the emergency department of Dr. Soetomo General Academic Hospital, Surabaya, and entered the ER (Resuscitation) ER room, but the patient died after being assisted for approximately two hours. Most likely the cause of the patient's death was a thromboembolic tumor in the right atrium that was released, so that it entered the bloodstream of the brain, causing the patient to have seizures. It was suspected that the cause of the patient's death was the presence of a tumor thrombus that separated into an embolism from the right atrium due to the large size of the tumor. Patients suffering from high rate NHL had a greater percentage of suffering from tumor thromboembolism as many as 10.6% compared to the Low type and Hodgkins lymphoma (LH) (5.8% and 7.25%).
Lymphocyte-t type th1 and th2 activity difference of lung tissue on heligmosomoides polygyrus nematode and mycobacterium tuberculosis sequential co-infection Wulandari, Laksmi; Amin, Muhammad; Soedarto, Soedarto; Soegiarto, Gatot
Folia Medica Indonesiana Vol. 53, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis that are often associated with uneffectiveness of the BCG vaccine and the high worm infection. The objective of this study was to determine the differences in the activity of Limfosit T type Th1 (IFN-g) and Th2 (IL-4) in lung tissue on Heligmosomoides polygyrus nematode and Mycobacterium tuberculosis sequential co-infection. This research using 49 mice were divide into 7 groups treated with infection by Mycobacterium tuberculose inhaled and Heligmosomoides polygyrus orally within 8 and 16 weeks. The levels of IFN-g in peripheral blood serum (89.929 + 3.533 pg/mL) resembles the pattern of the percentage of lymphocytes T CD4+ Th1 in lung tissue (3.246 + 0.519%) and peripheral blood (4.950 + 0.237%), while the levels IL-4 in the peripheral blood serum (20.782 + 4.043%) resembles the pattern of the percentage of lymphocytes T CD4+ Th2 in intestinal tissue (1.048 + 0.359%) and peripheral blood (1.196 + 0.557%). In conclusion, there is difference in the activity of lymphocytes T type Th1 and Th2 but it does not affect the immune response to Mycobacterium tuberculosis infection.
A 28-Year-Old Man With Mediastinal Seminoma Treated With BEP Rizki, Agustinus; Wulandari, Laksmi
Folia Medica Indonesiana Vol. 57, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Highlight: • A 28-year-old male suffered chylothorax and mediastinal seminoma. • The patient received bleomycin, etoposide and cisplatin chemotherapy for the management of mediastinal seminomas but he died beforeundergoing 5th cycle chemotherapy. Abstract: Seminoma is a type of germ cell tumor. In this case presentation, a rare primary germ cell tumor was reported in the form of mediastinal seminoma. A 28-year-old man with symptoms of shortness of breath, chest pain, swelling in the right upper extremity, enlarged lymph nodes in the colli region. Thoracic physical examination revealed signs of pleural fluid in the right hemithorax. After obtaining the results of radiological and pathological investigations, a mediastinal mass was obtained, then BEP chemotherapy was given. After 3 cycles of chemotherapy, a partial response was obtained. Patients with mediastinal seminoma treated with BEP base chemotherapy gave a partial response.
Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy Sahrun, Sahrun; Wulandari, Laksmi
Folia Medica Indonesiana Vol. 55, No. 3
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Various tyrosine kinase inhibitor (TKI) drugs have been widely used as therapy for cancer that has EGFR mutations, or abnormal EGFR activation. However, patients who have a mutation in the gene that activates EGFR only benefit from EGFR-TKI therapy for less than one year, because after that resistance occurs. In the management of patients according to NCCN 2017, patients who experience progress after receiving TKI as the first-line therapy must undergo an examination to identify the presence of T790M mutation. If the T790M mutation is positive, the choice of therapy that needs to be provided is the third generation (Osimertinib). Many recent studies have proved the significance of the effectiveness and response of Osimertinib therapy in lung cancer with EGFR T790M mutation. We reported the management of a pulmonary adenocarcinoma patient with positive EGFR mutation who had received first-line EGFR TKI who had progressive disease and T790M mutation in Dr. Seotomo Hospital. The patient finally received Osimertinib through an Early Access Program with a therapeutic response that improved significantly.
Comparison of chemotherapy response and adverse effects of double-platinum plus egfr-tki versus double-platinum alone on nslclc patients with disease progression and egfr-tki treatment Wulandari, Laksmi; Wiriansya, Edward Pandu
Folia Medica Indonesiana Vol. 53, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

EGFR-TKI is the first-line therapy for EGFR-mutant patients. Nevertheless, patients will have disease progression (median PFS 10 – 12 months) due to resistance. The treatment options are still limited in developing countries for such cases, thus double-platinum chemotherapy is the next option. Although IMPRESS study reported no difference in terms of PFS and OS between double-platinum alone and double-platinum plus EGFR-TKI, several local studies reported benefit of continuing EGFR-TKI in combination with double-platinum chemotherapy (treatment beyond progression). This study aimed to compare chemotherapy effects of double-platinum plus EGFR-TKI versus double-platinum alone on patients with NSCLC progression after EGFR-TKI treatment. This was an analytical descriptive study using prospective cohort design, involving 30 patients with disease progression following EGFR-TKI treatment that met inclusion criteria in Dr. Soetomo Hospital. Subjects were divided into two groups: arm A (double-platinum plus EGFR-TKI) and arm B (double-platinum alone). Subjects were observed until 4 cycles of double-platinum chemotherapy. Subjective response (body weight and EQ5D questionnaire) was analyzed, chest CT scans were evaluated using RECIST criteria, and adverse effects were monitored. This study was conducted in accordance with GCP principles and has received ethics certificate from Dr. Soetomo Hospital ethics committee (No. 08/Panke.KKE/I/2017). The results showed that subject characteristics between two arms were insignificantly different (p=0.05). The most common EGFR mutation was exon 21 (50% on arm A and 60% on arm B). Chi square was tested on subjective response parameter (EQ5D (p=0.483)). T2 free sample was tested on semi-subjective parameter (body weight (p=1.00)). Comparison test on both groups after cycle 2 and 4 showed p value=0.05. Statistical test on adverse effect between both groups showed p value=0.526. As a conclusion, there was no significant difference between double-platinum and double-platinum plus EGFR-TKI on patients who had disease progression following EGFR-TKI treatment.
PATTERNS OF RIFAMPICIN AND ISONIAZID RESISTANCE IN PULMONARY RR/MDR-TB WITH OR WITHOUT T2DM Sopha, May Ira; Wulandari, Laksmi; Rusli, Musofa; Husada, Dominicus; Prodjosoewojo, Susantina
Folia Medica Indonesiana Vol. 61, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Tuberculosis (TB) causes approximately[-12pc]AU: Please provide ORCID ID for all authors. 1.6 million deaths each year. The incidence of drug-resistant TB has continued to rise, primarily due to multidrug-resistant tuberculosis (MDR-TB). Drug-resistant TB remains a primary concern in various parts of the world, especially in Eastern Europe, Russia, Asia, and sub-Saharan Africa. This study aimed to analyze the correlation between first-line anti-tuberculosis drug resistance and the presence or absence of T2DM comorbidity in patients with pulmonary RR/MDR TB. This research employed a cross-sectional design, which used secondary data from 2023, obtained from medical records, the Tuberculosis Information System (SITB), and the results of first-line DST tests. The subjects included the RR-TB or MDR-TB patients with or without T2DM, treated at the MDR-TB outpatient clinic of Dr. Soetomo General Hospital, Surabaya. Of 131 patients, a portion had T2DM comorbidity. Statistical analysis showed no significant association between T2DM status and individual resistance to rifampicin (p = 0.247) or isoniazid (p = 0.312). However, clinically, patients with T2DM tended to exhibit more severe and complex resistance patterns. Although there was no statistically significant relationship between T2DM and first-line drug resistance, the presence of T2DM clinically indicated a tendency toward more severe resistance profiles.
Co-Authors Agustinus Rizki Aldise M Nastri Aldise Mareta Nastri Aldise Mareta, Aldise Ana Rima Ana Rima Setijadi Ananda, Fannie Rizki Andarini, Sita Andreas Infianto Anna Febriani Apriyanto, Yudi Arfiansyah, Mochammad Aris Arif Santoso Arif Santoso Ariobimo, Bonfilio Neltio Aris Widayati Arta Rahman Aryati Aryati Atik, Nurul Ayu Rahmanita Putri Soetrisno Cita Rosita Sigit Prakoeswa Dana Hendrawan Putra Delvac Oceandy Dewajani Purnomosari, Dewajani Dewajani Purnomosari3 Dewi, Gusti Agung Ayu Ira Kencana Djoko Poetranto, Djoko Dominicus Husada Duyen, Natalie Edith Frederika, Edith Elisna Syahruddin Emmanuel Djoko Poetranto Ermayanti, Sabrina Ermayanti, Sabrina Erwin Winaya Evelyn Asaleo Fahmita, Karin Dhia Farahannisaa, Kintan Adelia Febriani, Anna Ferry Dwi Kurniawan Gatot Soegiarto Gemilang Khusnurrokhman Gilang Muhammad Setyo Nugroho Grahana Ade Candra Wolayan Hamidah, Berliana Hanif, Muhammad Alfin Hariputri, Wulan Rahmawati Haryati Haryati Haryati Haryati Hayati, Fierly Hendra Ikhwan Gautama Hidayat, Moulid Husniyah, Barizatul Ida Ayu Jasminarti Ida Ayu Jasminarti Dwi Kusumawardani Indana Eva Ajmala Infianto, Andreas Jasminarti, Ida Ayu Juwita, Putri Mega Kazufumi Shimizu Khansa Fahira Wisdana Khusnurrokhman, Gemilang Kinanthi, Monica Tiara Arum Kurniawan, Ferry Dwi Kusdiantoro Kusdiantoro Kusdiantoro Kusdiantoro Landia Setiawati Lim, Darren Wan-Teck Linda Dewanti Lucia Landia Setyowati, Lucia Landia Luh Ade Wilan Krisna Lukisiari Agustini Lusida, Michael AP. Mahdi, Bagus Aulia Maqnun, Lu'lu'il Masaoki Yamaoka Masaoki Yamaoka, Masaoki Muhammad Amin Muhammad Dany Ramadhan Muhammad Fitra Ramadhan Nadira Putri Nastiti Nathaniel Aditya Neni Daniati Nikson Eduard Faot Nina Mauthia Noni Novisari Soeroso Novananda, Donny Ardika Novita Andayani, Novita Pakpahan, Cennikon Paladan, Triadi Putra Pradhevi, Lukita Pratama, Avissena Dutha Pratiwi, Suryanti Dwi Prodjosoewojo, Susantina Pudji Lestari Puteri, Rr. Astrid Aulia Artiono Putra, Andika Chandra Rebekah Setiabudi, Rebekah Resti Yudhawati Retno A Setyoningrum Retno Asih Retno Asih Setyoningrum Risnawati Risnawati Riyanto, Shandy Billy Rizki, Agustinus Rusli, Musofa Saefudin, Rendra P. Sahrun Sahrun Sahrun, Sahrun Santoso, Andintia Aisyah Setyawan, Ungky Agus Shivabasappa, Santhosh Sita Andarini Sita Ro'yul Aini Sjahjenny Mustokoweni, Sjahjenny soedarto soedarto, soedarto Sopha, May Ira Sri Melati Munir Sri Melati Munir Subagyo, Zaufy Verlieza Oktaviano Sulistiawati Sulistiawati Surya, Prima Ardiansah Susilowati Andajani, Susilowati Suwandi Syamsuri, Ibrahim Thendeyas, Richar Tomy Thirafi, Sacharissa Zerlina Tsarwah Tri Wibawa Utami Meilanie Putri Veda Septian Cahya Budi Vincent, Agustinus Wati, Farah Fatma Wibi Riawan Wiriansya, Edward Pandu Wiwin Is Effendi Yashinta, Yolanda Ayu Zahira Pelangi Rahmadilla Satriadi Zaini, Jamal Zaphiria Loka Pramesthi